BlossomHill raises $100M in bid to repeat founders’ cancer success at Turning Point

Blos­somHill Ther­a­peu­tics has closed a $100 mil­lion Se­ries B to bring three of its on­col­o­gy small mol­e­cules in­to the clin­ic and col­lect ear­ly ef­fi­ca­cy da­ta around the sec­ond half of 2025.

The San Diego biotech was cre­at­ed in 2020 by CEO J. Jean Cui and ex­ec­u­tive chair Y. Pe­ter Li, the co-founders be­hind Turn­ing Point Ther­a­peu­tics. Cui had served as chief sci­en­tif­ic of­fi­cer at Turn­ing Point, hav­ing been the lead in­ven­tor on its re­cent­ly ap­proved lung can­cer drug Aug­ty­ro. She left in mid-2020, pri­or to its $4.1 bil­lion sale to Bris­tol My­ers Squibb in 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.